Company intelligence / Profile preview

Cure8bio

Ownership: Private
Development stage: Preclinical

Overview

Cure8bio is pioneering advancements in regenerative medicine through stem cell therapies and gene editing. The company leverages a hub-and-spoke business model to develop curative therapies for chronic and previously untreatable diseases. Clinical results have not been published yet, indicating programs are likely preclinical or early-stage.

Therapeutic areas: OtherRare Diseases
Modalities: Stem cell therapiesGene editing
Industry: Biotech

Beyond the preview

Go deeper on Cure8bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cure8bio.

Explore the full profile